{"filing":{"accession_number":"0001145197-26-000132","cik":"0001145197","ticker":"PODD","company_name":"INSULET CORP","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"podd-20260526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1145197/000114519726000132/podd-20260526.htm"},"events":[{"id":8992,"run_id":7894,"accession_number":"0001145197-26-000132","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Insulet disclosed a voluntary medical device correction affecting approximately 7 million Omnipod® Pods due to manufacturing issues (cannula tears), with expected costs up to $50 million in 2026. While the company states it does not anticipate disruption to shipments or guidance changes, the scale of the correction (7 million units), the financial impact ($50 million), and the reputational/regulatory implications of a second related correction within months constitute a material event. This does not fit neatly into existing categories (not a restatement, impairment, or litigation settlement), making \"other_material\" the most appropriate classification.","company_name":"INSULET CORP","ticker":"PODD","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1462,"accession_number":"0001145197-26-000132","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Insulet disclosed a voluntary medical device correction affecting approximately 7 million Omnipod® Pods due to manufacturing issues (cannula tears), with expected costs up to $50 million in 2026. While the company states it does not anticipate disruption to shipments or guidance changes, the scale of the correction (7 million units), the financial impact ($50 million), and the reputational/regulatory implications of a second related correction within months constitute a material event. This does not fit neatly into existing categories (not a restatement, impairment, or litigation settlement), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:09:19.781135+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1462,"accession_number":"0001145197-26-000132","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Insulet disclosed a voluntary medical device correction affecting approximately 7 million Omnipod® Pods due to manufacturing issues (cannula tears), with expected costs up to $50 million in 2026. While the company states it does not anticipate disruption to shipments or guidance changes, the scale of the correction (7 million units), the financial impact ($50 million), and the reputational/regulatory implications of a second related correction within months constitute a material event. This does not fit neatly into existing categories (not a restatement, impairment, or litigation settlement), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:09:19.781135+00:00","company_name":"INSULET CORP","ticker":"PODD","filing_date":"2026-05-26"}]}